Needham analyst Serge Belanger has maintained their bullish stance on LQDA stock, giving a Buy rating today.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Serge Belanger has given his Buy rating due to a combination of factors that highlight the positive outlook for Liquidia Technologies. A recent court decision in favor of Liquidia has removed the final legal obstacle that could have delayed the FDA approval of their product, Yutrepia. This development is crucial as it clears the path for the anticipated approval of Yutrepia, which is expected to occur once the exclusivity period for a competing product, Tyvaso, ends in May 2025.
Belanger’s confidence in Liquidia’s prospects is further bolstered by the expected FDA approval for Yutrepia, which targets conditions such as PAH and PH-ILD. The removal of legal barriers and the upcoming expiration of Tyvaso’s exclusivity provide a favorable environment for Liquidia to capitalize on its market opportunities. These factors collectively contribute to the Buy rating, indicating a positive future performance for the company’s stock.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $35.00 price target.